ECSP993094A - NEW PHARMACEUTICAL USES FOR US INHIBITORS - Google Patents

NEW PHARMACEUTICAL USES FOR US INHIBITORS

Info

Publication number
ECSP993094A
ECSP993094A ECSP993094A ECSP993094A EC SP993094 A ECSP993094 A EC SP993094A EC SP993094 A ECSP993094 A EC SP993094A EC SP993094 A ECSP993094 A EC SP993094A
Authority
EC
Ecuador
Prior art keywords
combination
inhibitors
treatment
nos
alone
Prior art date
Application number
Other languages
Spanish (es)
Inventor
John Adams Lowe
Jolanta Nowakowski
Robert Alfred Volkman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP993094 priority Critical patent/ECSP993094A/en
Publication of ECSP993094A publication Critical patent/ECSP993094A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención hace referencia a nuevos usos farmacéuticos para compuestos que presentan actividad como inhibidores de la óxido nítrico sintetasa (NOS). Más especificamente, hace referencia al uso de inhibidores NOS y, en particular, a los inhibidores neuronales NOS (N-NOS) selectivos: (a) solos o en combinación con otro agente activo para el tratamiento de la psoriasis; (b) en combinación con un agente antiinflamatorio para el tratamiento de trastornos inflamatorios; (c) en combinación con un analgésico narcótico (opiáceos como la morfina o el demerol, por ejemplo) para el tratamiento del dolor; (d) solo o en combinación con otros agentes activos para el desarrollo de la capacidad cognitiva; y (f) solo o en combinación con otros agentes activos para el tratamiento de trastornos del sueño, como apnea, narcolepsia o insomnio.The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. More specifically, it refers to the use of NOS inhibitors and, in particular, selective NOS neuronal inhibitors (N-NOS): (a) alone or in combination with another active agent for the treatment of psoriasis; (b) in combination with an anti-inflammatory agent for the treatment of inflammatory disorders; (c) in combination with a narcotic pain reliever (opiates such as morphine or demerol, for example) for the treatment of pain; (d) alone or in combination with other active agents for the development of cognitive ability; and (f) alone or in combination with other active agents for the treatment of sleep disorders, such as apnea, narcolepsy, or insomnia.

ECSP993094 1999-08-11 1999-08-11 NEW PHARMACEUTICAL USES FOR US INHIBITORS ECSP993094A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP993094 ECSP993094A (en) 1999-08-11 1999-08-11 NEW PHARMACEUTICAL USES FOR US INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP993094 ECSP993094A (en) 1999-08-11 1999-08-11 NEW PHARMACEUTICAL USES FOR US INHIBITORS

Publications (1)

Publication Number Publication Date
ECSP993094A true ECSP993094A (en) 1999-10-06

Family

ID=42044081

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP993094 ECSP993094A (en) 1999-08-11 1999-08-11 NEW PHARMACEUTICAL USES FOR US INHIBITORS

Country Status (1)

Country Link
EC (1) ECSP993094A (en)

Similar Documents

Publication Publication Date Title
DE69826644D1 (en) TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A CHOLINERGIC ACTIVE SUBSTANCE OR A CALCIUM CHANNEL BLOCKER
MX9702527A (en) METHOD AND COMPOSITION OF STIMULATING NITRIC OXIDE SYNTHESIS.
BR9812523A (en) Process for preparing a transdermal delivery device, transdermal delivery device, and, using a steroid as an additive
ATE323473T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RESVERATROL AND USES THEREOF
TW200510375A (en) New compounds
ES2164040T1 (en) USE OF AGONISTS OF THE GLICINE UNION SITE OR INHIBITORS OF GLYCIN ABSORPTION FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS.
BR0309544A (en) Pharmaceutical preparation containing oxycodone and naloxone
DE69931055D1 (en) USE OF CYCLOOXYGENASE-2 INHIBITORS FOR TREATING INFLAMMATORY DISORDERS OF HEAD AND NECK
DK1100805T3 (en) Nitrate salts as a drug
ES2184145T3 (en) SULPHONIC ACID OR SULFONYLAMINE ACIDS-N- (HETEROARALQUIL) -AZAHETEROCICLILAMIDA.
CO5130011A1 (en) NEW PHARMACEUTICAL USES FOR INHIBITORS
GT200000071A (en) NEW PHARMACEUTICAL COMBINATIONS FOR INHIBITORS OF THE US.
TR200201071T2 (en) Emphysema treatment using Rar selective retinoid antagonists
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions
BR0207866A (en) Use of flumazenil in the preparation of a drug for the treatment of cocaine addiction
ECSP993094A (en) NEW PHARMACEUTICAL USES FOR US INHIBITORS
CO5261624A1 (en) NEW FENILHETEROALQUILAMINE DERIVATIVES, PROCESSES FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH NEW NOVEDOUS DERIVATIVES AND THEIR USE IN THERAPY
AR010432A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RICHINOLEIC ACID AND ITS USE FOR ANTI-INFLAMMATORY AND ANALGESIC THERAPY
ES2200403T3 (en) TREATMENT OF THE SYMPTOMS OF PARKINSON'S DISEASE WITH A MEDIA CONTAINING A SUBSTANCE THAT INCREASES THE CONCENTRATION OF DOPAMINE AND A LOCAL ANESTHETIC OF THE ANAILIDES GROUP.
BG105322A (en) New pharmaceutical use for nos inhibitors
BR0313305A (en) Analgesic agent for newborn or fetal individuals
BR0317772A (en) Method of treating a behavioral disorder, use of a compound, and therapeutic agent for a behavioral disorder
BRPI0412832A (en) therapeutic use of yessotoxins as inhibitors of human tumor cell growth
BR0015329A (en) Use of nitric oxide for the treatment of airway constriction
AR023763A1 (en) AGENT WHO POWERES THE RELEASE OF ACETILCOLINE IN THE BRAIN